01826: A Novel Treatment for Brain Tumors Using a One Medicine Approach

Grant Status: Closed

Grant Amount: $119,065
Simon R. Platt, BVMS; University of Georgia
January 1, 2013 - August 31, 2017

Sponsor(s): Collie Health Foundation, English Setter Association of America, Inc., Irish Setter Club of America Foundation, Newfoundland Club of America Charitable Trust

Breed(s): Bullmastiff
Research Program Area: Oncology
Donate to Support this Research Program Area


Drs. Simon Platt (University of Georgia College of Veterinary Medicine) and Costas Hadjipanayis (Emory University School of Medicine) will take a One Medicine approach to treating canine glioma brain tumors. Brain tumors in humans and animals are often devastating and fatal diseases. Many are not accessible to surgical removal which is the main treatment option. Likewise, chemotherapy has traditionally been ineffective because systemic delivery is prevented by the blood-brain barrier. In an effort to deliver chemotherapy drugs directly into brain tumors, a procedure called convection-enhanced delivery (CED) has been developed. This procedure utilizes small catheters, placed directly into tumors which allow direct drug delivery, limiting systemic drug concentrations, and therefore minimizing side effects. In this study dogs will undergo CED treatment with the monoclonal antibody cetuximab conjugated to magnetic iron-oxide nanoparticles (IONPs). Cetuximab is a monoclonal antibody specific to the epidermal growth factor receptor (EGFR) which is over-expressed in the majority of canine gliomas. Cetuximab is FDA-approved for use in several cancers in humans. When combined with IONPs, cetuximab can be visualized utilizing MRI. The dogs will be monitored clinically and with MRI over the next twelve months. The aim is a significant decrease in MRI volume of the tumors and ultimately, tumor-free survival of patients.


Freeman, A. C., Platt, S. R., Holmes, S., Kent, M., Robinson, K., Howerth, E., … Hadjipanayis, C. G. (2018). Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas. Journal of Neuro-Oncology, 137(3), 653–663. https://doi.org/10.1007/s11060-018-2764-1

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Connect With Us:
Get Canine Health News:
Please leave this field empty

© 2018 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software